Key Points {#FPar1}
==========

Administration of multiple daily oral doses of 40 mg omeprazole had no significant effect on the pharmacokinetics of a single oral dose of 100 mg roxadustat.The coadministration of multiple daily oral doses of 40 mg omeprazole and a single oral dose of 100 mg roxadustat was considered safe and well tolerated in healthy subjects.

Introduction {#Sec1}
============

Anemia is a common complication in patients with chronic kidney disease (CKD) that is caused, in part, by the inability of the failing kidneys to maintain adequate synthesis of erythropoietin (EPO), resulting in reduced levels of hemoglobin. Other etiological factors of anemia in CKD include altered iron homeostasis, shortened erythrocyte survival, and inflammation \[[@CR1]\]. Prevalence of anemia increases with the severity of CKD \[[@CR2], [@CR3]\] and is associated with an increased risk of cardiovascular comorbidities \[[@CR4]\], prolonged hospital stay \[[@CR5]\], reduced quality of life, and activity impairment \[[@CR6]\].

Current concerns regarding the safety of erythropoiesis-stimulating agent (ESA) therapy have caused a reduction in ESA use, leading to an unmet need for treatment of anemia in CKD \[[@CR7], [@CR8]\]. A novel class of therapeutic agents for the treatment of anemia in patients with CKD targets hypoxia-inducible factor, a family of oxygen-sensitive transcriptional factors that are modulated by prolyl hydroxylase enzymes and play a key role in regulating erythropoiesis \[[@CR7]\]. Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) increase endogenous EPO to levels that are observed during an acute bleed or chronic hypoxia states, which are significantly lower than the supraphysiologic peaks observed during treatment with intravenous ESA. Therefore, HIF-PHIs may provide an effective treatment for anemia in CKD without the adverse outcomes associated with ESA therapy \[[@CR9], [@CR10]\].

Roxadustat (ASP1517, FG-4592, AZD9941) is an orally active HIF-PHI currently in phase 3 investigation for the treatment of anemia in patients with CKD who are on or not on dialysis. Roxadustat has previously demonstrated safety and efficacy in phase 2 trials in patients with dialysis-dependent \[[@CR11]--[@CR13]\] and non-dialysis-dependent \[[@CR9], [@CR12], [@CR14]\] CKD. In addition to transiently increasing endogenous EPO levels, roxadustat has been shown to reduce the dysregulation of iron metabolism associated with CKD by increasing serum transferrin, intestinal iron absorption, and release of stored iron, in a dose-dependent manner \[[@CR9], [@CR12]\]. Roxadustat reaches its maximum plasma concentration in approximately 2 h after oral administration and has a terminal elimination half-life (t~½~) of 12--14 h after a single dose \[[@CR15]\]. Roxadustat is predominantly eliminated by phase I oxidation (cytochrome P450 \[CYP\] 2C8) and phase II conjugation (glucuronidation via uridine diphosphate-glucuronosyltransferase \[UGT 1A9\] and glucosidation). Furthermore, roxadustat is highly bound to proteins in human plasma, predominantly albumin. A DDI study in healthy volunteers revealed that roxadustat does not impact the maximum concentration (C~max~) or area under the concentration--time profile from the time of dosing extrapolated to infinity (AUC~inf~) of S- or R-warfarin, but does delay the time to reach maximum concentration (t~max~) of R-warfarin by approximately 1 h \[[@CR16]\]. The solubility of roxadustat in buffered aqueous solutions is pH dependent and increases from 0.001 mg/mL in a simulated gastric fluid buffer at pH 1.2 to 3.7 mg/mL in a 50 mM potassium phosphate buffer at pH 7.5 (data on file). Omeprazole is a proton pump inhibitor commonly used for the treatment of gastroesophageal reflux disease and peptic ulcer disease \[[@CR17]\]. Omeprazole increases gastric pH and may therefore increase the solubility of roxadustat and affect its absorption.

To evaluate whether gastric pH-raising drugs such as proton pump inhibitors impact roxadustat absorption, this study evaluated the impact of multiple daily oral doses of omeprazole on the pharmacokinetics of a single oral dose of roxadustat, as well as the safety and tolerability of a single oral dose of roxadustat alone or in combination with multiple daily oral doses of omeprazole.

Methods {#Sec2}
=======

Study Design {#Sec3}
------------

This was a phase 1, open-label, one-sequence, crossover study (1517-CL-0527; EudraCT 2014-000666-22) conducted at a single center (PAREXEL Early Phase Clinical Unit) in Berlin, Germany, consisting of a screening period (Day --22 to Day --2), followed by two treatment periods separated by a ≥ 7-day washout phase. During Period 1, subjects were admitted to the clinic on Day --1 and received a single oral dose of 100 mg roxadustat (ASP1517; Astellas Pharma, Inc.) on Day 1. Subjects remained in the clinic and were discharged on Day 4. Blood samples for roxadustat pharmacokinetic assessments were collected on Days 1--4. The starting doses in current phase 3 studies of patients with CKD not on dialysis range from 70 to 100 mg three times weekly and can be up- or down-titrated over a range of 20--300 mg three times a week. Therefore, the selected dose of 100 mg roxadustat truly represents a medium range and widely used therapeutic dose. This dose level in the present DDI study allowed for potential increases in roxadustat exposure due to the presence of omeprazole without any safety concerns \[[@CR9]\]. After a ≥ 7-day washout period, subjects were re-admitted to the clinic on Day --1 of Period 2. During Period 2, subjects received daily oral doses of 40 mg omeprazole (Antra MUPS^®^, AstraZeneca) on Days 1--9 and a single oral dose of 100 mg roxadustat on Day 7. Blood samples for roxadustat pharmacokinetic assessments were collected on Days 7--10 and blood samples for omeprazole pharmacokinetic assessments were collected on Days 1, 3, 5, and 7--10. Subjects were discharged on Day 10, and returned to the clinic for an end of study visit 5--9 days later for safety assessments. Since the recommended dose of omeprazole for the treatment of gastroesophageal reflux disease and peptic ulcer disease is 20--40 mg daily \[[@CR18]\], a regimen of daily administration of high doses of omeprazole (40 mg) on Days 1--7, before administration of a single oral dose of 100 mg roxadustat on Day 7, was chosen to maximize the interaction potential and to closely mimic real-life treatment conditions. Blood samples for pharmacokinetic analyses of roxadustat were collected pre- and post-dose at prefixed intervals during Period 1 and Period 2.

This study was conducted in accordance with the clinical study protocol, Good Clinical Practice, the International Council on Harmonisation guidelines, applicable regulations and guidelines governing clinical study conduct, and the ethical principles of the Declaration of Helsinki. The protocol was approved by an Independent Ethics Committee (Landesamt für Gesundheit und Sociales \[Ethik-Kommission des Landes Berlin\]) and all subjects provided written informed consent.

Study Objectives {#Sec4}
----------------

The primary objective was to determine the effect of multiple daily oral doses of 40 mg omeprazole on the pharmacokinetics of a single oral dose of 100 mg roxadustat. The secondary objective was to evaluate the safety and tolerability of a single oral dose of 100 mg roxadustat alone and in combination with multiple daily oral doses of 40 mg omeprazole.

Study Population {#Sec5}
----------------

Healthy male or female subjects, aged 18--55 years, with a body mass index of 18.5--29.9 kg/m^2^ were enrolled in this study. Female subjects were either of non-childbearing potential or must have had a negative serum pregnancy test at Day −1 and had to agree to use two forms of highly effective birth control from the time of screening to 28 days after final dosing. Male subjects, and their female partners of childbearing potential, had to agree to use two highly effective forms of birth control, and male subjects had to agree to not donate sperm from screening to 28 days after final dosing.

Key exclusion criteria included pregnancy within 6 months and breastfeeding within 3 months before screening; liver function tests above 1.5 × the upper limit of normal; use of any prescription or nonprescription drugs (including oral contraceptives) other than occasional paracetamol (up to 2 g/day) during the 2 weeks prior to the administration of the study drug until the end of study visit; a history of drinking \> 21 units (male subjects) or \> 14 units (female subjects) of alcohol (1 unit = 10 g pure alcohol, 250 mL of beer \[5%\], 35 mL of spirits \[35%\], or 100 mL of wine \[12%\]) per week or drugs of abuse in the 3 months before admission; and use of any drugs that induced metabolism within 3 months prior to admission. A complete list of inclusion and exclusion criteria is available in the Online Resource.

Study Drug Administration {#Sec6}
-------------------------

On Day 1 of Period 1, roxadustat was provided as a single 100 mg tablet with 240 mL of water after an overnight fast of at least 8 h, with the first meal provided 4 h after dosing. On Days 1--6 and Days 8 and 9 of Period 2, omeprazole was provided as a dose of 2 × 20 mg tablets once daily (for a total daily dose of 40 mg) with 240 mL water after an overnight fast of at least 8 h, and 30 min before breakfast. On Day 7 of Period 2, omeprazole was dosed first and roxadustat was dosed 2 h later; the first meal on Day 7 was provided 4 h after roxadustat administration.

Study Assessments {#Sec7}
-----------------

### Pharmacokinetic Assessments {#Sec8}

Blood sampling for roxadustat was conducted at predose, 30 min, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 60, and 72 h postdose on Days 1--4 of Period 1 and on Days 7--10 of Period 2. Blood sampling for omeprazole was conducted at predose on Days 1, 3, 5, and 7, and 30 min, 1, 2, 3, 4, 6, and 8 h postdose on Days 7 and predose on Days 8 and 9. Blood samples were obtained via a peripherally placed intravenous cannula or via direct venipuncture and collected into 3-mL tubes of sodium heparin. Blood samples were shipped to Astellas Drug Discovery Research/Bioanalysis Europe, and concentrations of roxadustat in human Na-heparin plasma were measured using a liquid chromatography tandem mass spectrometry method that was validated according to the European Medicines Agency bioanalytical method validation guidance (21 July 2011) \[[@CR19]\]. A stable isotope label (\[^13^C2, D3\]-roxadustat) was used as an internal standard. Roxadustat and the internal standard were extracted from 100 µl plasma by solid-phase extraction and separated by reversed-phase liquid chromatography on a C~18~ column using a gradient of water/acetonitrile; formic acid was used as the mobile phase. Detection was performed via tandem mass spectrometry on a 4000 QTrap mass spectrometer using positive Turbo ion spray ionization. The method was linear in the range of 1--1000 ng/mL; the lower limit of quantification was 1 ng/mL. The method was selective and did not show any evidence of carryover. The inter-run accuracy varied between −4.6 and 10.0% and the inter-run precision ranged between 0.7 and 4.2%. Concentrations of omeprazole in human Li-heparin plasma were also measured using a liquid chromatography tandem mass spectrometry method. A stable isotope labeled omeprazol-D3 was used as an internal standard. Omeprazole and the internal standard were extracted from 100 µl plasma by liquid--liquid extraction and separated by reversed-phase liquid chromatography on a C18 column. Detection was performed via tandem mass spectrometry on an API 4000 mass spectrometer using positive Turbo ion spray ionization. The method was linear in the range of 1--500 ng/mL with a lower limit of quantification of 1 ng/mL. The method was selective and did not show any evidence of carryover. The inter-run accuracy varied between −1.8 and 4.9% and the inter-run precision ranged between 2.4 and 9.3%. Pharmacokinetic parameters were calculated using Phoenix^®^ 6.2.1 (Certara, LP, St. Louis, MO, USA); non-compartmental methods were used to calculate the values of the pharmacokinetic parameters.

### Pharmacokinetic Endpoints {#Sec9}

Primary endpoints were area under the concentration--time profile from the time of dosing extrapolated to infinity (AUC~inf~) and maximum concentration (C~max~) for roxadustat in plasma. Secondary endpoints included area under the concentration--time profile to the last measurable concentration (AUC~last~), time to reach maximum concentration (t~max~), and t~½~.

### Safety {#Sec10}

Safety was assessed by evaluation of the nature, frequency, and severity of treatment-emergent adverse events (TEAEs), vital signs (blood pressure and pulse), clinical laboratory tests (hematology, biochemistry, and urinalysis), and routine 12-lead electrocardiogram (ECG). TEAEs were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Event guidelines (version 4.03) and were coded using Medical Dictionary for Regulatory Activities (MedDRA).

Statistical Methods {#Sec11}
-------------------

Based on a previous food-effect study (data on file) that showed a within-subject coefficient of variation of 16%, a sample size of 16 was determined to provide 90% power (NQUERY 7.0) to demonstrate the absence of effect of omeprazole on roxadustat pharmacokinetics. The absence of effect was to be concluded if the 90% confidence intervals (CIs) for the ratio of geometric means (i.e., roxadustat + omeprazole/roxadustat alone) for both AUC~inf~ and C~max~ were within the no-effect boundaries of 80.0 and 125.0%. A total of 18 subjects were enrolled to allow for dropouts.

The safety analysis set (SAF) comprised all subjects who received at least one dose of roxadustat. The pharmacokinetic analysis set, used for all pharmacokinetic analysis, included subjects who received at least one dose of study drug and had plasma concentration data available to determine at least one pharmacokinetic parameter.

Descriptive statistics were used to summarize demographic and baseline data and for pharmacokinetic parameters (i.e., number of subjects, arithmetic mean, standard deviation, % coefficient of variation, median, and range). Frequencies and percentages were used for categorical data. To assess the impact of omeprazole on the pharmacokinetics of roxadustat, the log-transformed AUC~inf~ and C~max~ for roxadustat was analyzed using a linear mixed effects model with treatment as a fixed effect and subject as a random effect. No imputation for missing data was performed.

Results {#Sec12}
=======

Subject Disposition {#Sec13}
-------------------

Of 42 subjects screened, 18 were enrolled, and 16 completed the study as per the clinical study protocol. One subject was excluded after receiving one dose of roxadustat during Period 1 due to receiving a prescribed medication (codeine), and one subject withdrew consent after receiving two doses of omeprazole during Period 2. Seventeen subjects (94.4%) received omeprazole on Day 1 and 2 of Period 2, and 16 subjects (88.9%) received omeprazole on Days 3--9 and roxadustat on Day 7 during Period 2. All 18 enrolled subjects were included in the SAF and pharmacokinetic analysis set. Subject baseline characteristics are displayed in Table [1](#Tab1){ref-type="table"}.Table 1Subject baseline characteristicsParameterTotal (*n* = 18)Sex, *n* (%) Male9 (50.0) Female9 (50.0)Race, *n* (%) Caucasian18 (100.0)Age (years) Mean (SD)44.4 (9.8) Median48.0 Range26--55Weight (kg) Mean (SD)71.1 (13.1) Median68.6 Range53.8--99.0Height (cm) Mean (SD)170.3 (7.4) Median171.5 Range159--186BMI (kg/m^2^) Mean (SD)24.3 (2.8) Median24.9 Range19.3--28.7*BMI* body mass index, *SD* standard deviation

Pharmacokinetics of Roxadustat {#Sec14}
------------------------------

The mean plasma concentration--time profiles of roxadustat administered alone (Day 1 of Period 1) and in the presence of omeprazole (Day 7 of Period 2) were similar (Fig. [1](#Fig1){ref-type="fig"}). Omeprazole had no significant effect on AUC~last~ or t~½~ of roxadustat (Table [2](#Tab2){ref-type="table"}). The ratio of geometric means (i.e., roxadustat + omeprazole/roxadustat alone) for both AUC~inf~ and C~max~ was within the no-effect boundaries of 80.0 and 125.0%, indicating that multiple daily oral doses of 40 mg omeprazole had no significant effect on the pharmacokinetics of roxadustat (Table [2](#Tab2){ref-type="table"}). Pharmacokinetic parameters for omeprazole were obtained to confirm exposure during coadministration with roxadustat. On Day 7, mean trough was 0.494 ng/mL, mean (SD) C~max~ was 1207 (705) ng/mL, and mean AUC from the time of dosing to the start of the next dosing interval was 4233 (3615) ng·h/mL.Fig. 1Mean plasma concentration profiles of roxadustat in subjects treated with roxadustat alone (*n* = 18), and roxadustat in the presence of omeprazole (*n* = 16). Error bars indicate standard deviation Table 2Pharmacokinetics of roxadustatParameterAUC~inf~ (ng·h/mL)C~max~ (ng/mL)t~max~ (h)AUC~last~ (ng·h/mL)t~½~ (h)Roxadustat alone (*n* = 18) Mean37,78163451.89737,51412.92 SD (% CV)10,628 (28.1)1298 (20.5)0.7552 (NA)10,496 (28.0)4.737 (36.7) Range19,572--57,4693173--84731.00--3.0019,359--57,2657.02--22.1 Median35,11965262.00035,02411.71Roxadustat + omeprazole (*n* = 16) Mean39,64267161.75839,27613.23 SD (% CV)13,317 (33.6)1980 (29.5)1.053 (NA)13,205 (33.6)5.18 (39.2) Range23,773--68,7293632--10,5010.500--4.0223,245--67,8017.42--27.0 Median37,68866611.50038,26212.02Geometric least squares mean ratio (roxadustat + omeprazole/roxadustat alone) % 104.53104.46 90% CI97.74--111.8090.99--119.93All means presented are arithmetic*AUC*~*inf*~ area under the concentration--time profile from the time of dosing extrapolated to infinity, *AUC*~*last*~ area under the concentration--time profile to the last measurable concentration, *CI* confidence interval, *C*~*max*~ maximum concentration, *CV* coefficient of variation, *NA* not applicable, *NC* not calculated, *SD* standard deviation, *t*~*½*~ terminal elimination half-life, *t*~*max*~ time to reach maximum concentration

Safety {#Sec15}
------

No serious TEAEs or TEAEs leading to permanent discontinuation of the study drug occurred. A total of six TEAEs were reported in six subjects (33.3%) after receiving roxadustat alone, eight TEAEs were reported in five subjects (29.4%) after receiving omeprazole alone, and two TEAEs were reported in two subjects (12.5%) after receiving roxadustat + omeprazole (Table [3](#Tab3){ref-type="table"}). The majority of TEAEs were considered by the investigator to be mild in severity, except for two TEAEs (abdominal pain and headache) reported by two subjects (11.1%) after receiving roxadustat alone, which were considered moderate in severity. The most commonly reported TEAEs were headache (*n* = 3, roxadustat alone; *n* = 1, omeprazole alone), diarrhea (*n* = 2, roxadustat alone; *n* = 1, omeprazole alone), and nasopharyngitis (*n* = 2, omeprazole alone; *n* = 1, roxadustat + omeprazole). Only one TEAE (dyspepsia/heartburn) reported by one subject after receiving omeprazole alone was considered by the investigator to be possibly related to the study drug, while all other TEAEs were not considered related to the study drug. No clinically significant changes in laboratory results, vital signs, or ECG findings were reported.Table 3Treatment-emergent adverse eventsMedDRA v15.1 system organ class\
 Preferred termRoxadustat alone (*n* = 18)Omeprazole alone (*n* = 17)Roxadustat + omeprazole (*n* = 16)Number of subjects with TEAE^a^6 (33.3)5 (29.4)2 (12.5)Gastrointestinal disorders3 (16.7)3 (17.6)0 Abdominal pain1 (5.6)00 Constipation01 (5.9)0 Diarrhea2 (11.1)1 (5.9)0 Dyspepsia01 (5.9)^b^0Infections and infestations03 (17.6)1 (6.3) Nasopharyngitis02 (11.8)1 (6.3) Oral herpes01 (5.9)0Investigations001 (6.3) Lymph node palpable001 (6.3)Nervous system disorders3 (16.7)1 (5.9)0 Headache3 (16.7)1 (5.9)0Respiratory, thoracic, and mediastinal disorders01 (5.9)0 Oropharyngeal pain01 (5.9)0Data are presented as *n* (%)*MedDRA* Medical Dictionary for Regulatory Activities*, TEAE* treatment-emergent adverse event^a^Subjects could report multiple TEAEs^b^Considered to be possibly related to study drug

Discussion {#Sec16}
==========

The objective of this study was to evaluate the effect of multiple daily oral doses of 40 mg omeprazole on the pharmacokinetics of a single oral dose of 100 mg roxadustat, and to assess the safety and tolerability of a single oral dose of 100 mg roxadustat alone or in combination with multiple daily oral doses of 40 mg omeprazole. The solubility of roxadustat increases with increasing pH in simulated gastric fluid buffers. Over the pH range of 1.2--7.5, the in vitro solubility of roxadustat increases from 0.001 to 3.7 mg/mL, suggesting that its absorption may be augmented by the concomitant administration of omeprazole, a commonly used drug that increases gastric pH. However, omeprazole 40 mg administered once daily in healthy subjects has been shown to increase gastric pH to \~ 5 \[[@CR20], [@CR21]\], and at this pH the in vitro solubility of roxadustat is still low (0.006 mg/mL). Therefore, only a fraction of the roxadustat dose would be dissolved in the stomach and a relative change in the absorption of roxadustat would not be detected. The results of this clinical study demonstrate that multiple daily oral doses of 40 mg omeprazole, which is the maximum of the commonly used therapeutic dose range (20--40 mg once daily), had no significant effect on the pharmacokinetics of a single oral dose of 100 mg roxadustat. The geometric least squares mean ratios for AUC~inf~ and C~max~ of roxadustat (with omeprazole/alone) were 104.53% (90% CI 97.74%, 111.80%) and 104.46% (90% CI 90.99%, 119.93%), respectively, and the 90% CIs were within the no-effect boundaries of 80.0 and 125.0%. Omeprazole is also an inhibitor of CYP2C19 \[[@CR18]\] and is typically associated with CYP-based interactions. Roxadustat is primarily metabolized via phase I oxidation and phase II conjugation and is not a substrate for CYP2C19; therefore, no CYP-mediated drug interactions were anticipated in this study. The combination of multiple daily oral doses of omeprazole with roxadustat was considered safe, and the majority of TEAEs reported were mild in severity. No serious TEAEs or TEAEs leading to permanent discontinuation of study drug or clinically significant changes in laboratory results, vital signs, or ECG findings occurred.

The lack of a significant effect of omeprazole on the pharmacokinetics of roxadustat indicates that an increase of gastric pH has no significant effect on the absorption of roxadustat, and suggests that the pharmacokinetics of roxadustat may not be impacted by other gastric pH-raising agents.

Conclusions {#Sec17}
===========

In healthy subjects, multiple daily oral doses of 40 mg omeprazole had no significant effect on the pharmacokinetics of a single oral dose of 100 mg roxadustat. Roxadustat was considered safe and well tolerated when administered alone or in combination with multiple daily oral doses of 40 mg omeprazole.
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